AAV manufacturing
AAV manufacturing
Unlocking Advanced Therapy’s Potential with AI: The Key Ingredients
🌍 Advanced therapy manufacturers must have robust hardware and monitoring software in place before benefiting from AI. 🤖📈
Revolutionary Approach to Manufacturing Macrophages
🧪💡✨ Meeting the Challenge of Manufacturing Macrophages explores how Resolution Therapeutics overcomes obstacles to produce effective macrophage therapy.
WuXi Biologics Supercharges Manufacturing with 5000L Bioreactors!
⚡ WuXi Biologics upgrades manufacturing capability with installation of three 5,000L single-use bioreactors! 🏭✨🔝
Revolutionary Genomic Tech Promises Cheaper Animal Vaccines
📅 June 3, 2024: High costs and technical difficulties limit animal vaccine development. 💉 New QTL technology offers affordable and effective vaccines. 🔬🚀
Revolutionary Cell Therapy Platform: Faster Cheaper and Automated!
🚀 Cytiva launches Sefia platform, speeding up cell-based treatments production. 💉 Sefia lowers costs, reduces errors, and saves time. 🔬 Scalable and flexible for all manufacturing stages. 💼 Direct marketing to customers.
Game-Changing Partnership: AGC Biologics and BioConnection Revolutionize Biodrug Development and Manufacturing
📢 AGC Biologics and BioConnection partner to offer end-to-end biopharmaceutical development and manufacturing services. 👥💊🌍⚠️🔒💡
Revolutionizing Cell Therapy Manufacturing: Cheaper and Accessible
📰 Getting the Economical Edge on Cheaper Cell Therapy Manufacturing explores Alder Therapeutics' cost-effective approach to therapy development. 💰🔬🧪🔬🔬🌱
Revolutionary Partnership Automates Cell Therapy Manufacturing for Age-Related Diseases
🙌 Multiply Labs and Retro Biosciences partner to automate cell therapy manufacturing for age-related diseases, valued at $85 million. 🌍
Revolutionary Automation System Cuts Cell and Gene Therapy Costs by 70
🤖 Vendor-agnostic automation system for cell and gene therapy manufacturing reduces errors and lowers costs.💡
Revolutionizing Cell Therapy Manufacturing: Faster & Safer
🔎 This article explores the challenges in cell therapy manufacturing and the urgency for faster processes. It discusses closed-process systems, bioreactors, and rapid testing methods to improve efficiency. It emphasizes the significance of streamlined manufacturing and quality control testing for faster treatment delivery. The need for a common manufacturing platform and scalability in cell therapy production is also addressed.
